Putative risk factors for failure and TTP
| Variable . | N . | Median TTP (mo) . | HR (95% CI) . | Log-rank P value . |
|---|---|---|---|---|
| Age ≥65 y | ||||
| Y | 31 | 30 | 0.88 (0.28-2.72) | .819 |
| N | 18 | NR | ||
| ≥4 prior lines of therapy | ||||
| Y | 27 | 30 | 2.03 (0.64-6.49) | .222 |
| N | 22 | NR | ||
| F-refractory | ||||
| Y | 24 | 22 | 7.02 (1.73-28.45) | .002 |
| N | 25 | NR | ||
| Bulky disease | ||||
| Y | 21 | 25 | 1.83 (0.61-5.49) | .276 |
| N | 28 | NR | ||
| Rituximab combination studies | ||||
| Y | 12 | NR | 0.50 (0.12-2.21) | .355 |
| N | 37 | 30 | ||
| Deletion 11q | ||||
| Y | 13 | NR | 0.34 (0.07-1.62) | .154 |
| N | 36 | 30 | ||
| Deletion 17p | ||||
| Y | 21 | 30 | 1.24 (0.40-3.87) | .709 |
| N | 28 | NR | ||
| Deletion 17p and/or TP53 mutation | ||||
| Y | 24 | 30 | 1.23 (0.34-4.41) | .752 |
| N | 16 | NR | ||
| Complex karyotype | ||||
| Y | 11 | 16 | 6.61 (1.47-29.75) | .005 |
| N | 19 | NR |
| Variable . | N . | Median TTP (mo) . | HR (95% CI) . | Log-rank P value . |
|---|---|---|---|---|
| Age ≥65 y | ||||
| Y | 31 | 30 | 0.88 (0.28-2.72) | .819 |
| N | 18 | NR | ||
| ≥4 prior lines of therapy | ||||
| Y | 27 | 30 | 2.03 (0.64-6.49) | .222 |
| N | 22 | NR | ||
| F-refractory | ||||
| Y | 24 | 22 | 7.02 (1.73-28.45) | .002 |
| N | 25 | NR | ||
| Bulky disease | ||||
| Y | 21 | 25 | 1.83 (0.61-5.49) | .276 |
| N | 28 | NR | ||
| Rituximab combination studies | ||||
| Y | 12 | NR | 0.50 (0.12-2.21) | .355 |
| N | 37 | 30 | ||
| Deletion 11q | ||||
| Y | 13 | NR | 0.34 (0.07-1.62) | .154 |
| N | 36 | 30 | ||
| Deletion 17p | ||||
| Y | 21 | 30 | 1.24 (0.40-3.87) | .709 |
| N | 28 | NR | ||
| Deletion 17p and/or TP53 mutation | ||||
| Y | 24 | 30 | 1.23 (0.34-4.41) | .752 |
| N | 16 | NR | ||
| Complex karyotype | ||||
| Y | 11 | 16 | 6.61 (1.47-29.75) | .005 |
| N | 19 | NR |
Univariate analyses of associations between putative risk factors for failure and TTP for all patients who received ≥400 mg/d of venetoclax. Variables were dichotomized: Y, present; N, absent; n, number with data for each variable group (where testing was not performed, data are not included).
NR, not reached.